• June 24, 2022

  EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP “KIGALI DECLARATION” FOR ELIMINATING NEGLECTED TROPICAL DISEASES
  CEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES

• June 22, 2022

  EISAI’S “NOUKNOW®”, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY

• June 22, 2022

  EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
  Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling

• June 8, 2022

  Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023

• June 6, 2022

  EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING
  Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)
  
  Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090)

View All

• June 17, 2022

  IR "Notice of Resolution of the 110th Ordinary General Meeting of Shareholders"

• May 24, 2022

  IR “Notice of Convocation of the 110th Ordinary General Meeting of Shareholders”

• May 16, 2022

  IR “Annual Financial Results Briefing for the Fiscal Year Ended March 31, 2022 [Material, Webcast]”

• May 13, 2022

  IR “Annual Financial Report for the Fiscal Year Ended March 31, 2022”

• April 28, 2022

  Recent hhc Activities“Contributing to Build a Community that Provides a Stress-Free Environment for People Living with Dementia, Where Enables Them to Live with Peace of Mind”

View All

• April 1, 2022

  Humanitarian Support to Ukraine

• November 24, 2021

  Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

• September 22, 2021

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY

• April 19, 2021

  Eisai formulates the action plan “Diversity & Inclusion 2021”

• December 3, 2020

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY

View All